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Abstract
Background: Clear cell renal cell carcinoma (ccRCC) is characterized by recurrent copy number alterations (CNAs)
and loss of heterozygosity (LOH), which may have potential diagnostic and prognostic applications. Here, we
explored whether ccRCC primary cultures, established from surgical tumor specimens, maintain the DNA profile of
parental tumor tissues allowing a more confident CNAs and LOH discrimination with respect to the original tissues.
Methods: We established a collection of 9 phenotypically well-characterized ccRCC primary cell cultures. Using the
Affymetrix SNP array technology, we performed the genome-wide copy number (CN) profiling of both cultures and
corresponding tumor tissues. Global concordance for each culture/tissue pair was assayed evaluating the
correlations between whole-genome CN profiles and SNP allelic calls. CN analysis was performed using the two
CNAG v3.0 and Partek software, and comparing results returned by two different algorithms (Hidden Markov Model
and Genomic Segmentation).
Results: A very good overlap between the CNAs of each culture and corresponding tissue was observed. The
finding, reinforced by high whole-genome CN correlations and SNP call concordances, provided evidence that
each culture was derived from its corresponding tissue and maintained the genomic alterations of parental tumor.
In addition, primary culture DNA profile remained stable for at least 3 weeks, till to third passage. These cultures
showed a greater cell homogeneity and enrichment in tumor component than original tissues, thus enabling a
better discrimination of CNAs and LOH. Especially for hemizygous deletions, primary cultures presented more
evident CN losses, typically accompanied by LOH; differently, in original tissues the intensity of these deletions was
weaken by normal cell contamination and LOH calls were missed.
Conclusions: ccRCC primary cultures are a reliable in vitro model, well-reproducing original tumor genetics and
phenotype, potentially useful for future functional approaches aimed to study genes or pathways involved in
ccRCC etiopathogenesis and to identify novel clinical markers or therapeutic targets. Moreover, SNP array
technology proved to be a powerful tool to better define the cell composition and homogeneity of RCC primary
cultures.
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The clear cell subtype of renal cell carcinoma (ccRCC)
accounts for 85% of all RCCs and occurs as familial or,
more often, sporadic forms. It is characterized by recur-
rent genetic anomalies, likec o p yn u m b e ra l t e r a t i o n s
(CNAs) and loss of heterozygosity (LOH), that involve
specific chromosomes (chrs) and result in deletions with
LOH on chrs 3p (often involving the von Hippel Lindau
(VHL) locus in 3p26-p25), 6q, 8p, 9p and 14q, and
duplications of chrs 5q and 7 [1-3]. Evidences suggest
that this peculiar pattern of genomic instability repre-
sents a tumor-specific molecular fingerprint useful for
diagnostic and prognostic applications [3-5]. However,
more work still needs to completely clarify the complex
molecular pathogenesis of ccRCC. Although the involve-
ment of the VHL tumor suppressor gene has been
demonstrated in all familial and in 80-90% sporadic
ccRCCs, the remaining 10-20% harbors wild-type VHL
[6,7], suggesting that, despite their identical histological
phenotype, these tumors have an intrinsic molecular
heterogeneity that still needs to be unraveled [6,8]. The
recognition of this molecular heterogeneity might
improve the selection of patients for targeted therapies
and allow the identification of specific oncogenes and
tumor suppressor genes to be used as novel clinical
markers or therapeutic targets.
The current availability of high-throughput platforms
to assess molecular changes at genome-wide level might
provide an opportunity to achieve this goal. Presently a
comprehensive and detailed genomic profiling of DNA
alterations is possible by using the single nucleotide
polymorphism (SNP) array technology. Unlike CGH
technique, the SNP array platform allows the simulta-
neous analysis of both chromosomal and allelic imbal-
ances [9] and the distinction between LOH associated
with CN changes (such as hemizygous deletions) and
CN neutral status (often termed as uniparental disomy)
[10]. In addition, this technology is able to provide
information about the fraction of normal and tumor
cells present in the tumor tissue samples [11]. This
allows a more complete definition of the complex
genetic rearrangements associated with cancer patholo-
gies. Moreover, since the regions of LOH accompanied
by deletion (representingt h es e c o n dh i to fK n u d s o n ’s
hypothesis) are of particular interest because they may
contain genes involved in tumor etiology, the assess-
ment of deletion/LOH areas represents a useful
approach to identify regions potentially harboring novel
tumor suppressor genes [12]. Accordingly, in a previous
study, we used the SNP array technology to characterize
the whole-genome DNA profile of a collection of
ccRCC tissue samples to find novel chromosomal
r e g i o n sa n dg e n e sp o t e n t i a l l yi n t e r e s t i n ga sc a n d i d a t e
tumor markers [13].
However, in ccRCC specimens, as in most solid tumor
tissues, the molecular analyses may be affected by tissue
heterogeneity due to the presence of necrotic areas and
non-tumor cells, such as tumor-infiltrating leukocytes,
endothelial cells and fibroblasts [14]. With the purpose
to increase the quality of data by minimizing this “back-
ground noise”, several different technical approaches
have been explored [15]. Tissue heterogeneity must be
considered also when evaluating which are the most
appropriate computational tools to process and analyze
array-based CN data [11,16].
Thus, to overcome the problem of tissue heterogeneity
and to prospectively perform in vitro functional studies
aimed to better understand ccRCC molecular pathogen-
esis, it is necessary to have a viable and more homoge-
neous cell material retaining the phenotypic and
genomic profile of original tissue. A possible strategy to
face these requirements is to adapt fresh ccRCC tissue
specimens to grow in vitro as primary cell cultures,
which provide a good quality, homogeneous and well-
characterized cellular material, enriched with tumor cell
component [17] and retaining at the first passages the
phenotypic and proteomic profile of the corresponding
tissues from which they derive [15,18,19]. Hence, pri-
mary cultures represent a better in vitro tumor model
than stable cell lines, that can be even very different
from the original tissues and thus not at all representa-
tive [6]. Anyway, the reliabi l i t yo fd a t ao b t a i n e df r o m
primary cultures strictly depends on their careful cytolo-
gical characterization, especially regarding possible cell
contaminations that might influence data interpretation
with misleading effects.
In this study, we investigated whether ccRCC primary
cultures, established from surgical tumor specimens and
phenotypically well-characterized, maintain the DNA
profile of parental tumor tissues and allow a better dis-
crimination of CNAs and LOH with respect to original
tissues. Till now, the comparison of DNA profile
between tumor primary cultures and parental tissues
has been reported, with discordant results, in melanoma
[20], neuroblastoma [21] and glioblastoma [22], using
either SNP array or array-CGH techniques, and in RCC
[23] only using traditional CGH on metaphase spreads
and short-term primary cultures not extensively
characterized.
Methods
ccRCC primary culture preparation and
immunophenotypic characterization
Nine ccRCC primary cultures were established from
corresponding surgical tissue specimens of ccRCC cases
(Table 1). Patients were enrolled in the research project
at Policlinico Hospital (University of Milan, Italy) and
provided informed consent for the research use of
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approved by the local ethic committee. All RCC cases
were diagnosed as “clear cell” subtype independently by
two pathologists with expertise in kidney cancer. Prior
to surgery, a whole blood sample was collected for each
case and stored at -20°C. Immediately after surgical
removal of the kidney, sections of fresh tissue samples
enriched in tumor component by needle dissection were
both stored at -80°C and collected in cold DMEM med-
ium supplemented with 10% fetal calf serum (FCS), 1%
penicillin/streptomycin, 1% amphotericin and 1% gluta-
mine (Culture Medium) and kept at 4°C until processing
(within 24 hrs). After removal of adipose and necrotic
areas, tumor tissues were mechanically minced in 1
mm
3-fragments and digested with 25 mg/ml collagenase
type IV (Sigma-Aldrich, St Louis, MO, USA) in DMEM
medium for 2 hrs at 37°C, vigorously vortexing every 15
minutes. Then, samples were washed three times in PBS
at 4°C and plated in 60 mm-Petri dishes or on glass
cover slips in the Culture Medium and incubated at 37°
Ci n5 %C O 2. Medium was changed twice weekly and
cells were 1:3 splitted when reaching 90% confluence.
Cell morphology was observed in contrast phase, at
100× magnification, by Olympus CK40 inverted micro-
scope (Olympus Corporation, Tokyo, Japan).
For immunofluorescence microscopy, ccRCC cells
grown on glass cover slips were fixed for 30 min in 4%
paraformaldehyde PBS buffer, pH 7.2, at 37°C, rinsed
with PBS, pre-incubated for 15 min in GDB buffer (0.02
mol/l sodium phosphate buffer, pH 7.4, with 0.45 mol/l
NaCl and 0.5% BSA) containing 0.3% Triton X-100, and
incubated with mouse monoclonal antibodies (mAbs)
against pan-cytokeratin (clone MNF-116, Dako,
Glostrup, Denmark; dilution 1:200), vimentin (clone V9,
Dako; dilution 1:200), carbonic anhydrase IX (CA9)
(clone M75, dilution 1:50; a gift from Prof. Pastorekova,
Institute of Virology, Slovak Academy of Sciences, Brati-
slava, Slovak Republic) and FITC-conjugated mAb
against CD13 (clone CBL 169F, Chemicon, Billerica,
MA, USA; dilution 1:25) for 2 hrs at room temperature.
After washing in PBS, cover slips were incubated for 1
hr with goat anti-mouse Alexa-Fluor488-conjugated IgG
secondary antibody (Molecular Probes, Invitrogen Life
Technologies, Carlsbad, CA, USA; dilution 1:100).
Nuclear counterstaining was performed by incubation
for 5 min with 1 μM DAPI (Sigma-Aldrich) in PBS buf-
fer. Immunofluorescence micrographs were obtained
using a Zeiss Axiovert 200 inverted microscope (Zeiss
Inc., Oberkochen, Germany), at 400× magnification,
equipped with a CoolSNAP HQ camera driven by Meta-
morph software. For flow cytometry analysis, cells at the
f i r s tc o n f l u e n c e( p 1 )w e r ed e t a c h e df r o mp l a t e sw i t h
0.25% trypsin-EDTA (Sigma-Aldrich), rinsed and incu-
b a t e df o r1 5m i ni nP B Sw i t h5 %F C S .F o rC D 1 3a n d
CA9 staining, cells were incubated for 15 min at room
temperature with the specific mouse mAbs. Cytokeratin
and vimentin staining was performed using the specific
mouse mAbs after permeabilization with IntraStain solu-
tion (Dako). Cells were then incubated with goat anti-
mouse Alexa-Fluor488-conjugated IgG secondary anti-
body (Molecular Probes, Invitrogen Life Technologies)
for 30 min at 4°C and counted by the FACSCalibur flow
cytometer and CellQuest software (BD Biosciences)
until 30,000 events were acquired.
Western Blot analysis
For each case, cells plated in a 6 mm-Petri dish were
l y s a t e dw h e na tt h ef i r s tc o n f l u e n c e( p 1 ) ,a n dt h e
extracted proteins quantified by the Bio-Rad microassay
(BioRad, Hercules, CA, USA), as previously described
[18]. 30 μg proteins were separated on NuPage 4-12%
Bis-Tris pre-cast gels (Invitrogen Life Technologies) and
blotted onto nitrocellulose membranes probed in 10
m MT r i s - H C l ,p H8 ,a n d3 %B S A ,w i t hm o u s em A b
against CA9 (clone M75, dilution 1:50). Detection was
performed using a secondary antibody coupled with
horseradish peroxidase for 1 hr at room temperature
and the SuperSignal West Pico detection system (Pierce,
Rockford, IL, USA).
DNA extraction and target preparation for Affymetrix SNP
Arrays
The genomic studies were performed on all ccRCC pri-
mary cultures at first confluence (p1); in addition, for
80MLa and 81BPG cases also cultures at second conflu-
e n c e( p 2 )o ra ts e c o n d( p 2 )a n dt h i r d( p 3 )c o n f l u e n c e s
were characterized. Genomic DNA was extracted from
primary cell cultures by QIAmp DNA Mini kit (Qiagen,
Hilden, Germany), according to manufacturer’sc u l t u r e d
cell protocol. DNA from tumor tissues and autologous
whole blood samples, used as normal control, was
extracted using a standard proteinase K cell lysis and
phenol-chloroform procedure. Samples were quantified
Table 1 Clinical data of the nine clear cell RCC cases from
which primary cultures have been prepared
Case Gender Age
(years)
Tumor size
(cm)
Tumor stage (pT)/
Grade
50PC M 51 5.7 pT1/G2
59RG M 72 5 pT1/G2
60CC M 78 11.5 pT3/G3
61FG M 56 5 pT1/G2
66SML F 48 9 pT2/G2
70LS M 71 4.4 pT1/G2
73PG F 75 2.5 pT1/G3
80MLa F 78 6.2 pT3/G2
81BPG M 69 3.3 pT1/G2
Cifola et al. BMC Cancer 2011, 11:244
http://www.biomedcentral.com/1471-2407/11/244
Page 3 of 12by ND-1000 spectrophotometer (NanoDrop Technolo-
gies, Wilmington, DE, USA) and checked by electro-
phoresis on 0.8% agarose gel. Starting from 250 ng,
DNA samples were processed using the GeneChip
®
Human Mapping 50K Hind Assay kit (Affymetrix, Santa
Clara, CA, USA), according to manufacturer’sp r o t o c o l ,
a n dh y b r i d i z e do n t oG e n e C h i p
® Human Mapping 50K
Hind Arrays. Intensity signals were acquired by Affyme-
trix GeneChip
® Scanner 3000 7G and quantified by
GTYPE v4.1 software (Affymetrix), using the BRLMM
algorithm to assign SNP calls and to generate CHP files.
A SNP call rate greater than 95% was considered as
“good quality” threshold.
Genome-wide copy number and LOH profiling in ccRCC
primary cultures and tumor tissues
To assess copy number alterations (CNAs) and loss of
heterozygosity (LOH), two different software CNAG
(version 3.0) and Partek Genomics Suite (version 6.5)
were applied. CNAG is a well known software com-
monly used to analyze SNP array derived-CN data in
tumor samples [24]. The AsCNAR (allele-specific copy-
number analysis using anonymous reference) algorithm
was applied to perform a “self-reference paired analysis”,
by comparing each culture and corresponding tumor tis-
sue to the matched blood sample. All resulting profiles
(global log ratio CN profiles; allele log ratio CN profiles;
Hidden Markov Model (HMM)-inferred CN state;
HMM-inferred LOH) were visually inspected to identify
regions affected by aberrations. To increase data reliabil-
ity, we chose to include only CNAs longer than 2 Mb
(resolution limit of 50K SNP array platform). CNAG
software was also used to obtain a genome-wide map of
LOH events occurring in each culture or tumor tissue
with respect to matched blood. Only the LOH events
defined as statistically significant by CNAG (with LOH
likelihood higher than 30, as default threshold, and thus
visualized in the HMM-LOH track) and covering
regions longer than 2 Mb were considered.
The same paired analysis was performed using Partek
G e n o m i c sS u i t es o f t w a r e( P a r t e kI n c . ,S tL o u i s ,M O ,
USA), starting from CEL intensity files and applying the
two alternative algorithms Hidden Markov Model
( H M M ,t h es a m eu s e db yC N A G )a n dG e n o m i cS e g -
mentation (GS). For HMM analysis, default parameters
were adopted; for GS analysis, the default window of 10
contiguous SNPs was maintained, Signal to noise ratio
at 0.5 and p-value at 0.001 were also adopted.
To estimate the global concordance between the geno-
mic profile of each primary culture and its parental tis-
sue, a paired whole-genome CN correlation was
calculated, starting from the CNAG “HMM-CN state”
data (SNP copy number status inferred by HMM), and
applying Spearman’s regression method. SNP call
concordance index and Spearman’s correlation between
the CNAG SNP allelic calls of two matched samples
were also calculated. For SNP call concordance, a con-
tingency table of the counts for each combination of the
four genotype categories (AA, AB, BB, NoCall) for cul-
ture (in row) and matchedt i s s u e( i nc o l u m n )w a s
accomplished. The concordance index was calculated as
a ratio between the sum of principal diagonal counts
and 56,859 (total number of real informative SNPs on
50K Hind arrays), multiplied by 100. A SNP call concor-
dance higher than 60% for two related samples was
adopted as threshold. All statistical analysis were per-
formed in R environment.
Results
Phenotypic characterization of ccRCC primary cultures
The nine ccRCC primary cultures established from sur-
gical tissue specimens reached the first confluence (p1)
in 8.0 ± 2.1 days. They grew well till reaching the fourth
confluence, and then began to slow down their growth
rate. In particular, 80MLa and 81BPG cultures reached
the second confluence (p2) after 13 days, and 81BPG
culture reached the third confluence (p3) after 20 days.
Cells exhibited heterogeneous epithelioid morphology,
were able to form foci and presented cytoplasmic
vacuoles frequent in clear cell RCC subtype during in
vitro growth (Figure 1a). Cytoplasmic staining specific
for the epithelial cytokeratin and for vimentin, a
mesenchymal marker expressed also in the epithelial
RCC cells, both in vivo and in vitro [18,25], and specific
expression of the proximal tubular marker CD13 were
observed in more than 90% of cells, as assessed by
immunofluorescence and FACS analysis, according to
the proximal tubular origin of ccRCC (Figure 1b).
Immunofluorescence and FACS analysis were performed
also with the monoclonal antibody against the trans-
membrane carbonic anhydrase IX (CA9) protein, one of
the most used biomarkers for ccRCC [26,27]. Our
ccRCC primary cultures showed the typical pattern of
membrane fluorescence and more than 60% of cells
were positive for CA9 (Figure 1b). Moreover, protein
lysates analyzed by Western Blot with anti-CA9 anti-
body showed the expected doublet at about 55 kDa in
all samples, except for 73PG culture (Figure 1c). On the
whole, these results confirmed the neoplastic phenotype
of our tubular primary cultures.
Genome-wide assessment of CNAs and LOH in ccRCC
primary cultures
The Affymetrix 50K SNP Array platform was used to
perform the whole-genome SNP profiling of 12 samples
from ccRCC primary cultures, nine at the first conflu-
ence (p1), two at the second confluence (p2), and one at
the third confluence (p3). In addition, 9 samples from
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gous blood samples were analyzed. We obtained an
average SNP call rate equal to 98.54%, ranging from
95.79% to 99.67%, and all arrays were included in the
analyses. Using CNAG v3.0 software, we performed the
genome-wide profiling of CNAs in each tumor primary
culture at p1. Globally, the typical “clear cell RCC”
genomic signature was confirmed, including deletions
on chr 3p and amplifications on chrs 5q and 7 (see
Additional File 1), the same signature that we previously
described in another set of ccRCC tissue samples [13].
Genome-wide comparison of DNA profile of primary
cultures and original tumor tissues
Our main purpose was to assess if ccRCC primary cul-
tures reflected the genomic profile of tumor tissues
from which they derived. First of all, for each tumor
primary culture/tissue pair, we calculated the global
correlation coefficient (by Spearman regression)
between their whole-genome CN profiles. Starting
from the HMM-CN state data generated by CNAG, we
obtained a mean CN correlation value equal to 0.73
(range 0.30-0.99) (Table 2). This wide range of varia-
tion was due essentially to 66SML sample, which pre-
sented the lowest CN correlation coefficient (Spearman
0.30). On the other hand, both the concordance index
and the Spearman’s correlation calculated on CNAG
SNP allelic calls gave very high values for all cases
(SNP call concordance indexes from 94% to 98% and
Spearman’s coefficients from 0.87 to 0.96), thus indi-
cating a strong correlation between cultures and corre-
sponding tissues at SNP genotype level, also for the
6 6 S M Lc a s e( T a b l e2 ) .
Figure 1 Phenotypic characterization of ccRCC primary cultures. (a) Representative cellular morphology during in vitro growth. 100×
magnification. (b) Representative micrographs of immunofluorescence staining (top) and FACS analysis (bottom) of pan-cytokeratin, vimentin,
CD13 and CA9. DAPI counterstains nuclei in blue. 400× magnification. The positivity percentages for the different markers are reported in the
FACS analysis as mean value (± SD) of the nine cultures. (c) Western Blot analysis of CA9 in all ccRCC primary cultures. B-actin was used as
internal control.
Table 2 Estimations of the global correlation between
the genomic profile of each primary culture and
corresponding parental tissue
Sample Spearman’s
correlation on HMM-
CN state
SNP call
concordance
index
Spearman’s
correlation on
SNP calls
50PC 0.66 98% 0.96
59RG 0.54 98% 0.96
60CC 0.94 94% 0.87
61FG 0.97 98% 0.96
66SML 0.30 96% 0.94
70LS 0.99 98% 0.96
73PG 0.68 97% 0.95
80MLa 0.60 97% 0.93
81BPG 0.90 95% 0.92
Cifola et al. BMC Cancer 2011, 11:244
http://www.biomedcentral.com/1471-2407/11/244
Page 5 of 12Looking at the individual CN profiles produced by
CNAG for each sample, 7 out of 9 primary cultures
exactly maintained all the DNA alterations presented by
the corresponding tumor tissues, or retained the normal
CN profile as observed in the original tissue (73PG case)
(Figure 2). The remaining two cultures presented the
DNA profile of parental tissues except for one CNA:
59RG culture did not show the chr 16p amplification
and 66SML culture did not show the chr 1p deletion
observed in the corresponding tissues. Moreover, four
primary cultures presented additional CNAs on one or
two chromosomes, not found in original tissues: 50PC
and 60CC cultures had an additional amplification on
chr 22q, 59RG showed amplification of chrs 2 and 7,
whereas 81BPG showed deletion with LOH on chrs 8p
and 14q (Figure 2).
Concerning LOH profile, 60CC culture exactly main-
tained all the allelic imbalances, with corresponding CN
status, found in the original tumor tissue, while 50PC,
61FG and 73PG cultures confirmed the absence of LOH
observed in parental tissues (Figure 2). The remaining
five primary cultures presented a total of 11 LOH
regions that were not detected by CNAG in original tis-
sues because not reaching the LOH likelihood threshold
to be classified as statistically significant by the software
and thus visualized in the HMM-LOH track. Viceversa,
we did not found LOH events occurring in tumor tis-
sues and not confirmed in corresponding cultures.
Additionally, we performed the whole-genome DNA
profiling of 80MLa culture also at second (p2) conflu-
ence (see Additional File 2) and of 81BPG culture at
second (p2) and third (p3) confluences (Figure 3). In
both cases, all the CNAs and LOH observed at p1 were
exactly maintained at p2 and p3, and no other altera-
tions occurred along passages. Even the deletions on
chrs 8p and 14q found in 81BPG culture at p1, but not
in original tissue, were confirmed at p2 and p3 (Figure
3). On the whole, these results indicated that the geno-
mic profile of ccRCC primary cultures highly reflected
that of parental tissues and remained stable during the
early passages, thus suggesting that these well-character-
i z e dp r i m a r yc u l t u r e sm a yb eag o o din vitro model of
original tumor tissues.
Moreover, when looking more in detail at the CN pro-
files calculated by CNAG, we observed that in six pri-
mary cultures (59RG, 61FG, 66SML, 70LS, 80MLa,
81BPG) the CN values of aberrant regions were more
definite in cultures than in parental tissues and this phe-
nomenon prevalently affected CN loss events. In the
66SML case, this situation was particularly evident. The
primary culture presented 4 wide CN loss regions on
chrs 2q, 3p, 9 and 14q. As shown in Figure 4 for chr 3p
Figure 2 Copy number alterations and LOH events in ccRCC primary cultures and parental tissues, as calculated by CNAG v3.0
software. On each chromosomal arm (p, short arm; q, long arm), amplifications (↑) and deletions (↓) and LOH events are reported for all
samples. Color labels distinguish CN alterations (CNAs) detected by CNAG and signed in the color-coded “HMM-CN state” track (red for
amplifications and dark green for deletions), and CNAs resulting below threshold to be visualized in the HMM-CN track (light green for
deletions). Only LOH events reaching significant likelihood to be signed by CNAG in the HMM-LOH track are reported.
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by pronounced negative CN values, easily classified by
CNAG software as statistically significant CN loss. This
deletion was present also in the parental tissue and was
visible in the CN profile. However, because of its less
pronounced CN values, it did not reach the software
threshold to be signed as statistically significant and did
not appear in the HMM-CN state track. In Additional
File 3 we reported other CN loss regions for 66SML
case and two other representative samples: calculating
the mean CN values corresponding to each of these
deletions, we always observed values more negative in
culture than in corresponding parental tissue. This
situation reflected also on LOH profiles. In fact, all the
11 LOH events previously mentioned as detected in pri-
mary cultures but not in parental tissues occurred in
such deleted regions presenting weak CN loss values in
tissues. As represented in Figure 4 for chr 3p in 66SML,
the software still detected thep r e s e n c eo fh e t e r o z y g o u s
SNP calls in parental tissue (green bars below chromo-
some ideogram), thus indicating that the hemizygous
deletion does not occur in all cells and suggesting the
presence of contaminating diploid cells. In all these
cases, LOH likelihood consequently decreased below
statistical significance threshold and these events were
m i s s e dt ob ev i s u a l i z e db yC N A Gi nt h eH M M - L O H
track, as illustrated in Figure 4 (see Additional File 3 for
LOH likelihoods of the other deleted regions). Thus, it
can be concluded that the increased cell homogeneity of
primary cultures, in term of tumor component, in com-
parison with their parental tumor tissues enabled a bet-
ter discrimination of CNAs and LOH.
Lastly, we performed the same paired analysis between
tumor primary culture and parental tissue using Partek
Genomics Suite software, which allows to choose
between two alternative CN algorithms. Globally, using
the HMM-based algorithm (the same used by CNAG),
Partek returned results overlapping with CNAG analysis.
Figure 3 Whole-genome view of copy number profile in 81BPG primary culture at first (p1), second (p2) and third (p3) confluences,
and in corresponding tumor tissue, using CNAG v3.0 software. Analysis was performed using CNAG v3.0 software, comparing primary
culture at each passage and parental tumor tissue to the autologous blood sample. Chromosomes are represented horizontally, from 1 to 22 in
different colors, separated by vertical bars. For each sample, the three tracks represent (on log scale): a) “copy number plot": copy number log
ratio values of single SNPs; b) “copy number average": copy number log ratio values locally averaged on 10 contiguous SNPs; c) “allele-based
analysis": copy number log ratio values for each allele (red and green lines).
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able to retrieve all those CN losses missed to be classi-
fied as statistically significant in tissue samples by the
CNAG HMM algorithm. This is illustrated for 66SML
case in Additional File 4. These results confirmed that
in tissue samples these deletions were really present
even if less visible than in cultures due to sample het-
erogeneity, and they did not arise de novo in primary
cultures.
Discussion
In this study, we investigated whether the in vitro model
of ccRCC primary cell cultures, established from surgical
tumor specimens, well reproduces the DNA profile of
parental tumor tissues, thus allowing a more confident
CNAs and LOH discrimination with respect to the ori-
ginal tissues. Tumor cells from ccRCC surgical speci-
mens may be adapted to in vitro growth with high
efficiency, independently from any clinico-pathological
characteristic of patients, as we previously confirmed
also in a wide series of well-characterized samples
[18,19]. The growth and survival rate of our ccRCC cul-
tures were in agreement with those reported by other
authors [14] and proved that our primary cultures grow
for the first four passages without difficulties [18]. The
cellular composition of our cultures was very homoge-
neous: more than 90% of cultured cells were of proximal
tubular origin, with morphological characteristics typical
of ccRCC, and more than 60% of cells were positive for
CA9, a biomarker present in almost all ccRCC cases
and expressed in most, although not all, of the malig-
nant clear cells of each single positive case [26,28].
When evaluated by Western Blot, CA9 expression was
quite strong in all samples, except for 73PG culture
where it was undetectable. Notably, about this latter cul-
ture, we found an identical normal genomic profile in
primary culture and parental tissue in terms of both
CNAs and LOH (with the resolution power of the 50K
SNP array platform), although the tumor tissue sample,
unlike primary culture, showed a CA9 expression by
immunohistochemistry (data not shown). This finding is
in agreement with another paper reporting a ccRCC
case which expressed CA9 in the surgical tissue sample
but not in the corresponding primary culture [15].
Moreover, in our experience with a wide series of sam-
ples [19], we observed other few ccRCC cases showing a
Figure 4 Visualization of chr 3 in 66SML primary culture (upper panel) and parental tissue (lower panel) using CNAG v3.0 software.
Chromosome 3 is shown from p to q end (from left to right). The upper two graphs represent single SNP copy number data on log2 scale (red
dots) and copy number values locally averaged on 10 contiguous SNPs (blue line), whereas copy number values for each allele (red and green
lines) are shown below. Green bars in the middle represent heterozygous SNP calls detected by the software comparing each sample to
autologous blood. The three bars at the bottom represent the color-coded visualization of HMM-CN state (yellow, diploidy; pink, amplification;
light blue, deletion) and of HMM-LOH state (blue, significant LOH; yellow, no LOH), with LOH likelihood indicated by the thickness of the third
blue bar. Boxes on the left report mean CN log2ratio values and mean LOH likelihoods calculated for the whole deleted region in primary
culture and tissue, respectively.
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Page 8 of 12CA9 positivity at tissue level but not in corresponding
primary cultures. Excluding tissue sampling mistakes,
this behavior might be due to a transitory expression of
CA9 during tissue excision. In fact, it is known that sur-
gical conditions, like tissue ischemia after renal artery
clamping and subsequent hypoxia, may up-regulate the
expression of downstream targets of HIF-1 (hypoxia
inducible factor 1), including CA9, that conversely
should not be induced under normoxic conditions like
those applied for primary cultures [29]. On the other
hand, the outgrowth of normal tubular epithelial cells in
73PG culture is unlikely based on the extensive pheno-
typic characterization we performed on all our cultures
[19].
Up to now, karyotypic characterization of RCC pri-
mary cultures has been performed only by classical cyto-
genetic G-banding [30] or CGH technique [23]. In our
knowledge, this is the first study applying the Affymetrix
SNP array technology to assess at genome-wide level
both CNAs and LOH in ccRCC primary cultures. Glob-
ally, our cultures confirmed the typical ccRCC genomic
signature [13,23,30]. These cultures typically showed
alterations on at most 4 or 5 chromosomes. Only two
samples made exception: 73PG culture did not show
alterations in both CN and LOH profiles, while 60CC
showed CNAs on all chromosomes. In particular, 60CC
primary culture, as well as its corresponding tissue,
showed an atypical ccRCC genomic profile more similar
to that of chromophobe subtype (characterized by wide
l o s s e so nc h r s1 ,2 ,6 ,1 0 ,1 3 ,1 7a n d2 1 ) ,n o t w i t h s t a n d -
ing its typical “clear cell” histology.
It should also be noted that while 73PG specimen
derived from a small in size tumor, suggestive of an
early stage of neoplastic progression, 60CC specimen
derived from the largest one, probably associated with
a more advance stage of tumor progression character-
ized by an aberrant and “clear cell” atypical genomic
profile [2].
Up today, very few genomic comparisons between
short-term primary cultures and parental tumor tissues
have been performed. In glioblastoma, for example, the
genomic profile of primary cultures, assessed by array-
CGH, resulted considerably different from that of paren-
tal tumors, with changes progressively occurring already
after 2 weeks of culture, resulting in an inconsistent
representation of tumor biology [22]. In melanoma [20]
and neuroblastoma [21], instead, using SNP array tech-
nology, primary cultures showed to encompass the spec-
trum of significant alterations present in primary
tumors, thus providing a genetically appropriate in vitro
model for functional genomics characterizations.
Concerning RCC, up till now the comparisons
between primary cultures and tumor tissues mainly
regarded phenotypic characterizations and proteomic
profiling [15,18,31]. A comparison of the genomic pro-
file between primary cultures and parental tissues has
been reported only by Sanjmyatav et al. by using tradi-
tional CGH [23]. Their DNA profiling showed a poor
overlap of CNAs between ccRCC primary cultures and
parental tumor tissues. In fact, only 3 out of 8 ccRCC
cultures exactly showed the same DNA alterations pre-
sent in the corresponding tissues. In addition, other 3
cultures did not show any of the CNAs found in the
corresponding tissue samples and resulted diploid. Prob-
ably, the poor overlap of CNAs obtained by Sanjmyatav
et al. [23] was due both to the low sensitivity and reso-
lution level of the technique used (i.e. CGH on meta-
phase chromosome spreads) and to the not extensive
cytological characterization of primary cultures. These
findings highlight the importance of a careful phenoty-
pic characterization of primary cultures for a correct
interpretation of genomic results.
Globally, these few genomic comparison studies
between primary cultures and parental tissues point out
that the use of tumor primary cultures as in vitro model
for genetic analysis or functional studies must be dis-
tinctively evaluated tumor by tumor and that in any
case it depends on the level of phenotypic characteriza-
tion of primary cultures.
Looking at the genome-wide CN profiles, our results
indicated that 7 out of 9 well-characterized primary cul-
tures exactly reproduced the DNA profile of the corre-
sponding tumor tissues. The other two cultures (59RG
a n d6 6 S M L )m a i n t a i n e da l lb u to n et h eC N A ss h o w e d
by the original tissues. These findings are in agreement
with Lin et al. who evidenced that in melanoma some
significant alterations present in original tissues (as a
deletion on chr 13q) were almost undetectable in cul-
tured cells, despite the landscape of genomic alterations
was strikingly similar [20]. However, it must be pointed
o u tt h a te v e ni fp r i m a r yc u l t u r e sm i g h th a v el o s ts o m e
genomic alterations present in original tumor tissues,
they probably correspond to some “passenger muta-
tions”, that do not confer selective growth advantage to
tumor cells and thus might be lost in cultured cells, and
not to “driver mutations” [32].
Although the good overlap of CN profiles between
each our primary culture and corresponding tissue, we
obtained a CN correlation mean value equal to 0.73 (by
Spearman regression method), a value just a little higher
than that reported for glioblastoma cultures and tissues
(Pearson mean 0.62) [22]. The reason is in the wide
range of variance we obtained among our 9 cases (range
0.30-0.99), mainly due to the contribution of one case
(66SML) on the mean. Although this variability seems
too high for conclusive messages, it must be noted that
in our series it essentially depends on a software issue.
In fact, we used the CNAG “HMM-CN state” data, that
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rithm and visualized in the HMM-CN state track. How-
ever, in the presence of a high sample heterogeneity, as
in the case of 66SML tissue (illustrated in Figure 4), the
HMM-CN state data missed to detect CN aberrations,
even if present, because their CN values did not reach
the software threshold for a statistical significance. For
this reason, the 66SML sample had the lowest CN cor-
relation coefficient between culture and tissue (Spear-
man 0.30), a value that does not really reflect a poor
overlap but only a software constraint.
Similarly to those found in neuroblastoma [21], the
SNP call concordance indexes and the Spearman’sc o r -
relation coefficients calculated on CNAG SNP allelic
calls indicated a strong correlation at SNP genotype
level between our cultures and parental tissues, 66SML
sample included, thus confirming that each primary cul-
ture really derived from its corresponding tissue.
Notably, in six samples, CNAs were more evident and
better discriminated in primary cultures than in corre-
sponding tumor tissues. This phenomenon principally
occurred in deleted regions and it is due to the different
cellular composition of the two samples and it was also
observed in neuroblastoma tissues and derived cell lines
[21]. Tumor tissues are heterogeneous and comprise a
mixture of tumor and normal cells (endothelial cells,
leukocytes, fibroblasts). For this reason, the copy num-
ber values corresponding to DNA alterations of tumor
cells are inevitably “diluted” by the diploid values com-
ing from normal cells. Differently, primary cultures were
more homogeneous in terms of tumor component, as
shown by their phenotypic characterization, and thus
presented better defined CNAs. Tumor tissue heteroge-
neity reflects also on LOH detection. In fact, the soft-
ware used in the analysis not only detected the allele
retained by the tumor, but also the second allele still
present in normal cells; in these cases the LOH call will
be missed [33]. In our ccRCC primary cultures, instead,
hemizygous deletions were accompanied by LOH calls,
confirming the great sample homogeneity that enables
to discriminate CNAs and LOH. Thus, the presence of
LOH calls in deleted regions could be adopted as a
parameter to evaluate the degree of tumor sample purity
and the level of normal cell contamination and conse-
quently the origin of cultured cells, highlighting the
power of SNP array technology with respect to CGH
technique. Such an evidence appears more important
taking into account that since today there is not a single
universally applied method able to certainly make these
evaluations [34].
The high cell homogeneity observed in our ccRCC
cultures might explain also the additional CNAs found
in 4 of them but not in original tissues. The acquisition
of these alterations de novo during in vitro growth is
unlikely since cultures were analyzed at first confluence.
Moreover, the genomic analysis of some cultures at sec-
ond and third confluences provided evidence that these
cultures did not accumulate further alterations during
passages and remained stable for at least 3 weeks. We
could therefore conclude that these alterations might
fail to be seen in the heterogeneous tumor tissues
because present in a very small number of cells (< 20%),
thus resulting undetectable for CN analysis algorithms
[11,24].
Actually, the true picture of genomic alterations
occurring in a tumor can be obtained only performing a
genomic analysis directly on tumor cells isolated, for
example, by laser capture microdissection, which allows
a > 90% of purity [35] and circumvents the problem of
DNA alteration “dilution” due to tissue heterogeneity.
However, such a useful technical approach has the not
negligible inconvenience of providing cellular material
not exploitable for eventual subsequent functional
studies.
Conclusions
By performing the genome-wide copy number profiling
of a collection of ccRCC primary cultures and corre-
sponding tumor tissues, we demonstrated that these
well-characterized primary cultures maintained the
genomic alterations of parental tumors. Moreover, their
DNA profile remained stable for at least 3 weeks, till to
third confluence. Importantly, RCC primary cultures
provided greater cell homogeneity and enrichment in
tumor component than parental tissues, as proved also
by phenotypic characterization, thus enabling a better
discrimination of DNA alterations. In this context, SNP
array technology demonstrated to be a powerful tool
able to confirm the origin of cultured cells and to evalu-
ate sample homogeneity and normal cell contamination.
The observation that ccRCC primary cultures retain not
only the phenotypic features and the proteomic profile
of original tumor tissues but also their genomic profile
proves that these short-term cultures are a reliable in
vitro model that well represents ccRCC genetics and
biology and that prospectively could be used for func-
tional approaches.
Additional material
Additional file 1: Whole-genome maps of CN alterations and LOH
events in the nine ccRCC primary cultures, using CNAG v3.0
software. Chromosomes are represented from p to q end (from left to
right), with cytobands (black and white blocks), centromeres (green
blocks) and heterocromatic regions (red and blue blocks). (a) Starting
from the HMM-CN state data, regions of CN gain (upper red traces) and
CN loss (lower green traces) are represented along each chromosome
(from1 to 22). (b) Regions of statistically significant LOH (with LOH
likelihood higher than 30) are represented with red traces along each
chromosome. Chromosome X was excluded from analyses.
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Page 10 of 12Additional file 2: Whole-genome view of copy number profile in
80MLa primary culture at first (p1) and second (p2) confluences,
and in corresponding tumor tissue, using CNAG v3.0 software.
Analysis was performed using CNAG v3.0 software, comparing primary
culture at each passage and parental tumor tissue to the autologous
blood sample. Chromosomes are represented horizontally, from 1 to 22
in different colors, separated by vertical bars. For each sample, the three
tracks represent (on log scale): a) “copy number plot": copy number log
ratio values of single SNPs; b) “copy number average": copy number log
ratio values locally averaged on 10 contiguous SNPs; c) “allele-based
analysis": copy number log ratio values for each allele (red and green
lines).
Additional file 3: Copy number and LOH likelihood values for
selected deleted regions in primary cultures and corresponding
tissues, as calculated by CNAG v3.0 software. Starting from the
Hidden Markov Model (HMM) copy number log2ratios exported for each
SNP by CNAG v3.0 software, we calculated the mean CN log ratio value
for each region (start and end positions are reported), both in primary
cultures and parental tumor tissues. Also, mean LOH likelihood values
were calculated for primary cultures and corresponding tissues. In the
“CNAG detection” column, we define “CN loss signed” those deletions
reaching software threshold to be visualized in the color-coded HMM-CN
state track; similarly, “LOH signed” are those events considered as
statistically significant by CNAG (with LOH likelihood higher than 30) and
thus visualized in the color-coded HMM-LOH track.
Additional file 4: Partek Genomics Suite analysis: CN loss detection
in 66SML primary culture and parental tissue by applying the two
different algorithms HMM (Hidden Markov Model, the same used
by CNAG software) and GS (Genomic Segmentation). Analysis was
performed starting from CEL intensity files produced by Affymetrix GCOS
software, and comparing each ccRCC primary culture and parental tissue
to its autologous blood sample. Two different algorithms were used:
HMM (Hidden Markov Model) and GS (Genomic Segmentation). Here we
reported an example of the different output returned by the two
algorithms for 66SML case. On the five chromosomes here displayed
(chrs 1p, 2q, 3p, 9, 14q), the CN loss regions, even if clearly visible in the
log ratio CN track (upper graph, in log2 scale), failed to be signed by the
HMM algorithm in the tissue sample (middle track), exactly as observed
in CNAG analysis. Differently, the GS algorithm was able to retrieve all
these regions in tissue sample, visualizing them as green bars (bottom
track).
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